These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140 [TBL] [Abstract][Full Text] [Related]
4. Intrarenal vascular resistance parameters in kidney transplant patients receiving calcineurin inhibitor-based or sirolimus-based regimens. Lee PC; Lee CY; Hu RH; Lo C; Tsai MK; Lee PH Nephrol Dial Transplant; 2010 May; 25(5):1675-80. PubMed ID: 20042398 [TBL] [Abstract][Full Text] [Related]
5. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Segundo DS; Ruiz JC; Izquierdo M; Fernández-Fresnedo G; Gómez-Alamillo C; Merino R; Benito MJ; Cacho E; Rodrigo E; Palomar R; López-Hoyos M; Arias M Transplantation; 2006 Aug; 82(4):550-7. PubMed ID: 16926600 [TBL] [Abstract][Full Text] [Related]
6. Treatment with everolimus is associated with a procoagulant state. Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938 [TBL] [Abstract][Full Text] [Related]
7. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508 [TBL] [Abstract][Full Text] [Related]
8. Results of 4-year analysis of conversion from calcineurin inhibitors to mTOR inhibitors in renal transplant patients: single-center experience. Sert M; Celik A; Kural K; Ersan S; Ataca P; Atila K; Cavdar C; Sifil A; Bora S; Gulay H; Camsari T Ren Fail; 2011; 33(8):789-94. PubMed ID: 21787153 [TBL] [Abstract][Full Text] [Related]
9. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination. Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355 [TBL] [Abstract][Full Text] [Related]
10. Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization? Gonzalez-Vilchez F; Vazquez de Prada JA; Paniagua MJ; Gomez-Bueno M; Arizon JM; Almenar L; Roig E; Delgado J; Lambert JL; Perez-Villa F; Sanz-Julve ML; Crespo-Leiro M; Segovia J; Lopez-Granados A; Martinez-Dolz L; Mirabet S; Escribano P; Diaz-Molina B; Farrero M; Blasco T Int J Cardiol; 2014 Jan; 171(1):15-23. PubMed ID: 24309084 [TBL] [Abstract][Full Text] [Related]
11. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients. Potter BJ; Giannetti N; Edwardes MD; Cecere R; Cantarovich M Clin Transplant; 2007; 21(3):305-8. PubMed ID: 17488377 [TBL] [Abstract][Full Text] [Related]
12. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. Kushwaha SS; Khalpey Z; Frantz RP; Rodeheffer RJ; Clavell AL; Daly RC; McGregor CG; Edwards BS J Heart Lung Transplant; 2005 Dec; 24(12):2129-36. PubMed ID: 16364861 [TBL] [Abstract][Full Text] [Related]
13. Management of chronic allograft dysfunction by switch over to rapamycin. Sundaram V; Abraham G; Fathima N; Sundaram V; Reddy YN; Mathew M; Sathiah V Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):37-42. PubMed ID: 20061690 [TBL] [Abstract][Full Text] [Related]